Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
[en] The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Allez, Matthieu
Karmiris, Konstantinos
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects.
Publication date :
2010
Journal title :
Journal of Crohn's and Colitis
ISSN :
1873-9946
eISSN :
1876-4479
Publisher :
Elsevier, Amsterdam, Netherlands
Volume :
4
Issue :
4
Pages :
355-66
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2010 European Crohn's and Colitis Organisation. All rights reserved.
Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 59:1541-1549.
Colombel J.F., Sandborn W., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
Schreiber S., Khaliq-Kareemi, Lauwrance I.C., Thomsen O.Ø., Hanauer S.B., McColm J., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999, 340:1398-1405.
Lichtenstein G.R., Yan S., Bala M., Blank M., Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
Feagan B.G., McDonald J., Panaccione R., et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gut 2008, 57(sII):A66.
Sandborn W.J., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., Mason D., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007, 357:228-238.
Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442.
Lémann M., Mary J.Y., Duclos B., Veyrac M., Dupas J.L., Delchier J.C., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054-1061.
Colombel J.F., Rutgeerts P., Reinisch W., et al. A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut 2008, 57(sII):A1.
Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
Marting A., Belaiche J., Louis E. Long term safety and efficacy of infliximab in routine practice. Acta Gastroenterol Belg 2007, 10:D45.
González-Lama Y., López-San Román A., Marín-Jiménez I., Casis B., Vera I., Bermejo F., et al. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterol Hepatol 2008, 31:421-426.
Vermeire S., Louis E., Carbonez A., Van Assche G., Noman M., Belaiche J., et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002, 97:2357-2363.
Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
Van Assche G., Vanbeckevoort D., Bielen D., Coremans G., Aerden I., Noman M., et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003, 98:332-339.
Hyder S., Travis S., Jewell D., Mortensen N., Georges B. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006, 49:1837-1841.
Topstad D.R., Panaccione R., Heine J.A., Johnson D.R., MacLean A.R., Buie W.D. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003, 46:577-583.
Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
Regueiro M., Siemanowski B., Kip K.E., Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007, 13:1093-1099.
Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104:760-767.
Sandborn W.J., Hanauer S.B., Rutgeerts P.J., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II Trial. Gut 2007, 56:1232-1239.
Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
Mortimore M., Gibson P.R., Selby W.S., Radford-Smith G.L., Florin T.H. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 2001, 31:146-150. Schering Plough (Australia).
Farrell R.J., Alsahli M., Jeen Y.T., Falchuk K.R., Peppercorn M.A., Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003, 124:917-924.
Baert F., Noman M., Vermeire S., Van Assche G., D' Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
Zabana Y., Cabre D.E. Infliximab reintroduction in patients with inflammatory bowel disease previously treated with a 3-infusion induction regimen is not associated to a higher rate of immune mediated adverse effects. J Crohn's Colitis 2008, 2(36). Suppl.
Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheumatol 2005, 34:12-18.
Hwang W.Y.K., Foote J. Immunogenicity of engineered antibodies. Methods 2005, 36:3-10.
Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
St Clair E.W., Wagner C.L., Fasanmade A.A., Wang B., Schaible T., Kavanaugh A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451-1459.
Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
Karmiris K., Paintaud G., Noman M., Magdelaine-Beuzelin C., Ferrante M., Degenne D., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926.
Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
Vermeire S., Abreu M., D'Haens G., Colombel J.F., Mitchev K., Fedorak R., et al. Efficacy and safety of Certolizumab Pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the welcome study. Gastroenterology 2008, 134:A67-A68.
Allez M., Vermeire S., Mozziconacci N., Michetti P., Laharie D., Louis E., et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010, 31:92-101.
Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonists mechanisms of action: a comprehensive review. Pharmacol Therapeut 2008, 117:224-279.
Vermeire S., Noman M., Van Assche G., Baert F., D'Haens G., Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
Svenson M., Geborek P., Saxne T., Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007, 46:1828-1834.
Candon S., Mosca A., Ruemmele F., Goulet O., Chatenoud L., Cézard J.P. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006, 118:11-19.
Ainsworth M.A., Bendtzen K., Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008, 103:944-948.
Bendtzen K., Ainsworth M., Steenholdt C., Thomsen O.O., Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009, 13:1-8.
Bendtzen K., Geborek P., Svenson M., Larsson L., Kapetanovic M.C., Saxne T. Individualized monitoring of drug bioavailability and immunogenecity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789.
Wolbink G.J., Vis M., Lems W., Voskuyl A.E., de Groot E., Nurmohamed M.T., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715.
Van de Putte L.B.A., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508-516.
Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2008, 68:1739-1745.
Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
Bennett A.N., Wong M., Zain A., Panayi G., Kirkham B. Adalimumab-induced asthma. Rheumatology 2005, 44:1199-1200.
Aarden L., Ruuls S.R., Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008, 20:431-435.
Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
Bender N.K., Heilig C.E., Dröll B., Wohlgemuth J., Armbruster F.P., Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007, 27:269-274.
West R.L., Zelinkova Z., Wolbink G.J., Kuipers E.J., Stokkers P.C., van der Woude C.J. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008, 28:1122-1126.
Tabrizi M.A., Tseng C.M., Roskos L.R. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006, 11:81-88.
Wang W., Wang E.Q., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008, 84:548-558.
Brambell F.W. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet 1966, 2:1087-1093.
Ghetie V., Hubbard J.G., Kim J.K., Tsen M.F., Lee Y., Ward E.S. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996, 26:690-696.
Ghetie V., Ward E.S. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 1997, 18:592-598.
Raghavan M., Bonagura V.R., Morrison S.L., Bjorkman P.J. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995, 34:14,649-14,657.
Dall'Acqua W.F., Woods R.M., Ward E.S., Palaszynski S.R., Patel N.K., Brewah Y.A., et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002, 169:5171-5180.
Hinton P.R., Xiong J.M., Johlfs M.G., Tang M.T., Keller S., Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006, 176:346-356.
Ober R.J., Radu C.J., Ghetie V., Ward E.S. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001, 13:1551-1559.
Indik Z.K., Park L.G., Hunter S., Schreiber A.D. The molecular dissection of Fc gamma receptor mediated phagocytosis. Blood 1995, 86:4389-4399.
Kumpel B.M., De Haas M., Koene H.R., Van De Winkel J.G., Goodrick M.J. Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16). Clin Exp Immunol 2003, 132:81-86.
Maini R.N., Breedveld F.C., Kalden J.R., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563.
Bunescu A., Seideman P., Lenkei R., et al. Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 2004, 31:2347-2355.
